Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
In this prospective pilot study, we aim to evaluate 1) the tolerability and safety, 2) the efficacy of 12 weeks once-daily fenofibrate in reducing IC incidence after DCD liver transplantation, 3) assess the association between serum markers of cholestasis and development of IC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have undergone Donation after Circulatory Death (DCD) liver transplantation (LT).
At least one serum alkaline phosphatase level \>2.5x upper limit of normal between post-LT days 21-60 (inclusive).
You may not be if
LT performed for primary sclerosing cholangitis or primary biliary cholangitis.
Untreated biliary anastomotic stricture or bile leak between days 0-60 after LT
Renal dysfunction defined as baseline glomerular filtration rate \< 30 ml/min.
Previously known intolerance or allergy to fenofibrate.
Other clinically significant comorbid condition, including psychiatric conditions, which in the opinion of the study team, may interfere with patient treatment, safety, assessment, or compliance with the treatment.
Adults lacking capacity to consent to treatment
Clareo Health | A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation
